NECi tehisintellekt toetab arste endoskoopiliste protseduuride ajal Barretti söögitoru neoplaasia tuvastamisel

TOKYO, May 28, 2021 – (JCN Newswire) – NEC Corporation (NEC; TSE: 6701) today announced the development of an AI technology for supporting doctors to detect neoplasia in Barrett’s esophagus during endoscopic procedures. This is the world’s first technology of its kind to comply with the requirements for CE mark labeling, a European safety, health and environmental protection standard (1), and is being released as WISE VISION Endoscopy, where it will soon be available in Europe to help doctors in the detection of Barrett’s neoplasia (2).

Provided by Professor Pradeep Bhandari: “Once the neoplasia is found, the system takes a still image and transfers it to the top right corner of a screen as a reference image for endoscopists. It also has a heat map which shows the area of the AI-predicted neoplasia.”

This software is connected to endoscopy processors and automatically notifies users of potential Barrett’s neoplasia from images captured during endoscopic procedures.

Barrett’s esophagus is a pre-cancerous condition in which the inner lining of the esophagus is replaced by a lining that resembles that of the stomach. Worldwide prevalence of Barrett’s esophagus is 1% of the entire population but much higher (7%) in patients with acid-reflux symptoms (3). Patients with Barrett’s esophagus have 30-40 fold higher risk of developing cancer of the esophagus as compared to the normal population (4).

However, if this cancer can be detected at an early stage, then it can be removed through the endoscope and a patient can be cured. Patients with Barrett’s esophagus have to undergo regular endoscopy (every 2-3 years) to detect early cancer, but this is still challenging as the early changes of cancer are very subtle and difficult to identify. As a result, current recommendations are to take multiple random biopsies throughout the length of Barrett’s esophagus to identify any focus of early cancer (5, 6). However, random biopsies are expensive and time consuming and are only performed in accordance with official clinical guidelines by an estimated 30-51% of endoscopists (7, 8, 9, 10). Consequently, it has been pointed out that up to 40% of neoplasia may be missed (7) resulting in delayed cancer diagnosis and poor outcomes for the patients.

To help resolve this issue, NEC collaborated with Professor Pradeep Bhandari (Portsmouth, UK), Chair of the European Society of Gastrointestinal Endoscopy (ESGE) Research Committee, in development of this new technology to support doctors to detect Barrett’s neoplasia during examination. WISE VISION Endoscopy has been trained with more than 1 million Barrett’s esophagus endoscopy images, together with the knowledge of expert endoscopists, enabling it to meet the requirements for CE mark labeling. In developing this solution, NEC applied its face recognition technology that has been highly evaluated (11) by the National Institute of Standards and Technology (NIST) in the United States, and belongs to NEC’s portfolio of cutting-edge AI technologies, “NEC the WISE.”

On clinical evaluation, WISE VISION Endoscopy could find more than 90% of Barrett’s neoplasia (12). WISE VISION Endoscopy is expected to significantly reduce the neoplasia miss rate during endoscopy and improve the outcome for patients with Barrett’s esophagus all around the world.

Seda tehnoloogiat rakendav kokkuvõte on pälvinud Briti Gastroenteroloogia Seltsi (BSG) Gut Award auhinna, mis anti üle BSG ülikoolilinnaku plenaaristungil. Samuti valiti see United European Gastroenterology korraldatud UEG Week Virtual 2020 üheks parimaks endoskoopia kokkuvõtteks.

“I am delighted that NEC, as one of the world’s leaders in AI technology, has entered the field of endoscopy and developed WISE VISION? Endoscopy to detect and help manage Gastrointestinal neoplasia. Barrett’s neoplasia can be very flat and easily missed during endoscopy, despite taking multiple biopsies. I worked with NEC to develop the Barrett’s neoplasia detection arm of WISE VISION? Endoscopy and am super impressed by the speed with which NEC has produced this as the World’s first AI engine to obtain the CE mark for notifying Barrett’s neoplasia.

“WISE VISION Endoscopy can notify very flat and subtle lesions and much faster than most endoscopists. Once the neoplasia is found, this system takes a still image and transfers it to the top right corner of a screen as a reference image for endoscopists. It doesn’t stop here, as it also has a heat map which shows the area of the AI-predicted neoplasia. WISE VISION? Endoscopy is set to revolutionize the endoscopic detection and management of Barrett’s neoplasia in the western world. I’m sure that clinicians involved in the management of Barrett’s esophagus are looking forward to the dawn of this new (Wise) era in Endoscopy,” said Professor Pradeep Bhandari, Chair of the ESGE Research Committee.

WISE VISION Endoskoopiast

Seda tarkvara saab ühendada kolme juhtiva endoskoobitootja endoskoopidega (13). Ühendades olemasoleva endoskoobi lihtsalt tarkvaraga varustatud monitori ja terminaliga, saavad kasutajad seda kohe kasutama hakata. Süsteem väljastab heliteatisi, kui kahjustuskandidaat on leitud, ning teate tüüpi ja helitugevust saab igal ajal vastavalt kasutaja eelistustele kohandada. Lisaks võimaldab hästi nähtav kasutajaliides intuitiivset kasutamist, võimaldades spetsialistidel tõrgeteta uuringutega edasi minna.

Edaspidi on NEC-i eesmärk kiirendada digitaalset ümberkujundamist meditsiinivaldkonnas, pakkudes ohutuid ja turvalisi tooteid ja teenuseid, sealhulgas tehisintellekti, et edendada tervet ja jätkusuutlikku ühiskonda, kus üksikisikud saavad arenenud IT-tehnoloogiate kasutamise tõttu areneda.

(1) Allikas: NEC Corporation
(2) WISE VISION on NEC Corporationi registreeritud kaubamärk Ameerika Ühendriikides, Euroopa Liidus ja Ühendkuningriigis.
(3) Marques de S? I, Marcos P, Sharma P, Dinis-Ribeiro M. The global prevalence of Barrett’s esophagus: A systematic review of the published literature. United European Gastroenterol J. 2020;8(9):1086-1105. doi:10.1177/2050640620939376
(4) Sharma P. Clinical practice. Barrett’s esophagus. N Engl J Med. 2009 Dec 24;361(26):2548-56. doi: 10.1056/NEJMcp0902173. Erratum in: N Engl J Med. 2010 Apr 15;362(15):1450. PMID: 20032324.
(5) Weusten B, Bisschops R, Coron E, Dinis-Ribeiro M, Dumonceau JM, Esteban JM, Hassan C, Pech O, Repici A, Bergman J, di Pietro M. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy. 2017 Feb;49(2):191-198. doi: 10.1055/s-0042-122140. Epub 2017 Jan 25. PMID: 28122386.
(6) ASGE STANDARDS OF PRACTICE COMMITTEE, Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, Anandasabapathy S, Agrawal D, Buxbaum JL, Fishman DS, Gurudu SR, Jue TL, Kripalani S, Lee JK, Khashab MA, Naveed M, Thosani NC, Yang J, DeWitt J, Wani S; ASGE Standards of Practice Committee Chair. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. 2019 Sep;90(3):335-359.e2. doi: 10.1016/j.gie.2019.05.012. PMID: 31439127.
(7) Kariv R, Plesec TP, Goldblum JR jt. Seattle'i protokoll ei ennusta vähktõve avastamist söögitoru eemaldamise ajal usaldusväärsemalt kui vähem intensiivne seireprotokoll. Kliiniline gastroenteroloogia ja hepatoloogia: Ameerika Gastroenteroloogia Assotsiatsiooni ametlik kliinilise praktika ajakiri. 2009 juuni;7(6):653-8; viktoriin 06. PubMed PMID: 19264576. Epub 2009/03/07. ing.
(8) Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol. 2016;
(9) Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011 Mar;140(3):e18-52; quiz e13.
(10) Abrams JA, Kapel RC, Lindberg GM, Saboorian MH, Genta RM, Neugut AI, et al. Adherence to Biopsy Guidelines for Barrett’s Esophagus Surveillance in the Community Setting in the United States. Clin Gastroenterol Hepatol [Internet]. 2009 Jul 1 [cited 2018 Nov 16];7(7):736?42.
(11) NEC näotuvastustehnoloogia on NIST-i täpsustestimisel esikohal
https://www.nec.com/en/press/201910/global_20191003_01.html
(12) Esitleti Euroopa Seedetrakti Endoskoopia Ühingu korraldatud ESGE päevadel 2021
(13) Ühenduvus ja toimingud on kinnitatud järgmiste endoskoopidega.
Olympus EVIS LUCERA ELITE videosüsteemikeskus CV-290
Olympus EVIS EXERA III videosüsteemikeskus CV-190
FUJIFILM ELUXEO videoprotsessor VP-7000
PENTAX Medical OPTIVISTA EPK-i7010 videoprotsessor
PENTAX Medical OPTIVISTA EPK-i7000 videoprotsessor

Rohkem informatsiooni
URL: https://www.nec.com/en/global/wisevision/?id=confirm

Teave NEC Corporationi kohta

NEC Corporation on tõestanud end IT- ja võrgutehnoloogiate integreerimise liidrina, propageerides samal ajal brändiavaldust "helgema maailma korraldamine". NEC võimaldab ettevõtetel ja kogukondadel kohaneda nii ühiskonnas kui ka turul toimuvate kiirete muutustega, kuna see tagab sotsiaalsed väärtused nagu turvalisus, turvalisus, õiglus ja tõhusus, et edendada jätkusuutlikumat maailma, kus kõigil on võimalus oma potentsiaal täielikult ära kasutada. Lisateabe saamiseks külastage NEC-i aadressil https://www.nec.com.

Allikas: https://www.jcnnewswire.com/pressrelease/66926/3/